Zynerba misses in Phase II for OA

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) lost $0.61 to $6.42 on Monday after reporting that its synthetic cannabidiol (CBD) gel ZYN002 missed the primary endpoint in the Phase II STOP trial to treat knee pain due to osteoarthritis. Last Monday, the company fell 56% to $6.67 after ZYN002 missed the primary endpoint in the Phase II STAR 1 trial to treat focal seizures in adult epilepsy patients (see BioCentury Extra, Aug. 7).

Despite the miss, Zynerba said it plans to continue development of ZYN002 in OA, with a Phase III program slated to start next year. On a conference call to discuss the data, CEO Armando Anido said the company believes "the totality of the data from the trial provides us with confidence that ZYN002 shows promise for the treatment of OA and there is a path forward in the pivotal studies."...